The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis
Abstract
In rheumatoid arthritis (RA), interleukin-6 (IL-6) concentration is elevated, which may cause reduced cytochrome P450 (CYP) activity and increased exposure (peak plasma concentration and area under the plasma concentration-vs.-time curve (AUC)) to certain drugs. Tocilizumab may reverse IL-6-induced suppression of CYP3A4 activity. In this study, exposure to simvastatin was significantly reduced at 1 and 5 weeks after tocilizumab infusion in 12 patients with RA. The mean effect ratio for simvastatin AUC(last) was 43% (90% confidence interval (CI), 34-55%) at 1 week after tocilizumab infusion (day 15) and 61% (90% CI, 47-78%) at 5 weeks after tocilizumab infusion, as compared with baseline (day 1); both ratios were significantly lower than the bioequivalence boundary (80-125%). Mean plasma C-reactive protein (CRP) levels normalized within 1 week after tocilizumab was initiated; the time course of tocilizumab's CRP-reducing effect paralleled that of simvastatin pharmacokinetics. The study findings suggest that caution should be exercised when starting tocilizumab in RA patients who are taking simvastatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smolen, J. S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., Woodworth, T., & Alten, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60453-5 · Cited by 1,399
Emery, P., Keystone, E., Tony, H. P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J., & Kremer, J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092932 · Cited by 1,104
Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., & Gomez‐Reino, J. J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23940 · Cited by 855 · cited 1×
“Cmax, ng/ml 36 (22) 14 (6) 43 (33–55) 22 (18) 60 (46–76)”
Jones, G., Sebba, A., Gu, J., Lowenstein, M. B., Calvo, A., Gomez-Reino, J. J., Siri, D. A., Tomšič, M., Alecock, E., Woodworth, T., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.105197 · Cited by 797
Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., & Kakehi, T. (2008) · Blood · doi:10.1182/blood-2008-05-155846 · Cited by 795
Maini, R. N., Taylor, P. C., Szechinski, J., Pavelka, K., Bröll, J., Balint, G., Emery, P., Raemen, F., Petersen, J., Smolen, J., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22033 · Cited by 790
Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease
Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4602 · Cited by 754
Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., & Nishimoto, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.012 · Cited by 636
REGULATION OF DRUG-METABOLIZING ENZYMES AND TRANSPORTERS IN INFLAMMATION
Aitken, A. E., Richardson, T. A., & Morgan, E. T. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141059 · Cited by 448
Aitken, A. E., & Morgan, E. T. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015511 · Cited by 398
Madhok, R., Crilly, A., Watson, J., & Capell, H. A. (1993) · Annals of the Rheumatic Diseases · doi:10.1136/ard.52.3.232 · Cited by 340
Mihara, M., Kasutani, K., Okazaki, M., Nakamura, A., Kawai, S., Sugimoto, M., Matsumoto, Y., & Ohsugi, Y. (2005) · International Immunopharmacology · doi:10.1016/j.intimp.2005.05.010 · Cited by 328
Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90151-5 · Cited by 286
Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.
Sato, K., Tsuchiya, M., Saldanha, J. W., Koishihara, Y., Ohsugi, Y., Kishimoto, T., & Bendig, M. M. (1993) · PubMed · Cited by 274
Jover, R., Bort, R., Gómez‐Lechón, M. J., & Castell, J. V. (2002) · The FASEB Journal · doi:10.1096/fj.02-0195fje · Cited by 221
Nishimoto, N., Yoshizaki, K., Maeda, K., Kuritani, T., Deguchi, H., Sato, B., Imai, N., Suemura, M., Kakehi, T., Takagi, N., et al. (2003) · PubMed · Cited by 203
Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin
Lilja, J. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.110216 · Cited by 187
Molecular and cellular biology of interleukin-6 and its receptor
Keller, E. T. (1996) · Frontiers in Bioscience · doi:10.2741/a136 · Cited by 182
Prueksaritanont, T., Ma, B., & Yu, N. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01833.x · Cited by 180
Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations
Kyrklund, C. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.111414 · Cited by 163
Robak, T., Gladalska, A., Stepień, H., & Robak, E. (1998) · Mediators of Inflammation · doi:10.1080/09629359890875 · Cited by 161
Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin
Lilja, J. J., Neuvonen, M., & Neuvonen, P. J. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02095.x · Cited by 157
Hirano, T. (2015) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000420758 · Cited by 148
Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis
Sack, U., Kinne, R. W., Marx, T., Heppt, P., Bender, S., & Emmrich, F. (1993) · Rheumatology International · doi:10.1007/bf00307733 · Cited by 127
Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis
Frey, N., Grange, S., & WOODWORTH, T. G. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009350623 · Cited by 126
Self-citationYu, R. Z., Geary, R. S., Flaim, J., Riley, G. C., Tribble, D. L., vanVliet, A. A., & Wedel, M. K. (2008) · Clinical Pharmacokinetics · doi:10.2165/0003088-200948010-00003 · Cited by 103
The Biology of Interleukin-6 (Part 1 of 2)
Hirano, T. (1992) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000319085 · Cited by 74
Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort.
Okamoto, H., Koizumi, K., Kamitsuji, S., Inoue, E., Hara, M., Tomatsu, T., Kamatani, N., & Yamanaka, H. (2007) · PubMed · Cited by 63
Najib, N. M., Idkaidek, N., Adel, A., Dmour, I. M., Astigarraga, R. E. B., Nucci, G. D., Alam, S. M., Dham, R., & Qumaruzaman (2003) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.347 · Cited by 40
Cited by
(2012) · The Lancet · doi:10.1016/s0140-6736(11)61931-4 · Cited by 823
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
Current trends in drug metabolism and pharmacokinetics
Li, Y., Meng, Q., Yang, M., Liu, D., Hou, X., Tang, L., Wang, X., Lyu, Y., Chen, X., Liu, K., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.10.001 · Cited by 391
Therapeutic Targeting of the Interleukin-6 Receptor
Tanaka, T., Narazaki, M., & Kishimoto, T. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134715 · Cited by 262
The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review
Huang, S.-M., & Rowland, M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.320 · Cited by 150
Metadata
- Authors
- Schmitt, C., Kuhn, B., Zhang, X., Kivitz, A. J., & Grange, S.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2011-03-23
- Volume
- 89
- Issue
- 5
- Pages
- 735-740
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2015244046
- Cited by
- 257
- References
- 29
- FWCI
- 15.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.